Microbot Medical to Fully Launch LIBERTY System in 2026

Microbot Medical is continuing to generate significant market and new customer momentum as it enters 2026. In 2025, the Company met its milestones, including several pivotal achievements such as obtaining FDA 510(k) clearance for LIBERTY, the first single-use, remotely operated robotic system for peripheral endovascular procedures. The Company initiated its limited market release, quickly achieving its first customer to adopt LIBERTY for patient care. The Company is positioning itself to leverage this momentum and commercialize LIBERTY across a targeted U.S. market of 2.5 million peripheral endovascular procedures annually. This progress enables the Company to pursue and strive for the 2026 anticipated milestones listed. Anticipated 2026 Operational and Commercial Milestones Commence the Full Market Release of the LIBERTY System in Q2 2026, in conjunction with the Society of Interventional Radiology conference. Grow customer base by attracting early adopters and securing new hospitals with medium-to-high volume target procedures. Validate the LIBERTY System's significant market opportunity, with the expansion of the types of procedures that are being performed as well as the end user call point to include interventional radiologists, vascular surgeons, and interventional cardiologists. Establish commercial and operational infrastructure to support expansion into markets outside the USA, either under FDA Clearance or other regional and local regulatory approvals. Enhance the Company's core capabilities by filling cross-functional roles with the right talent to support execution and future growth. Maintain a strong presence at key medical societies and conferences, including the Society of Interventional Oncology and International Symposium on Endovascular Therapy in February, Society of Interventional Radiology in April, Global Embolization Symposium and Technologies in May and Cardiovascular and Interventional Radiological Society of Europe in September. Continue to establish pipelines to allow future growth to other interventional spaces and increase the utilization opportunity within the peripheral space. Continue collaborations with leading institutions in the areas of teleintervention and autonomous robotics and explore additional opportunities to leverage the innovative LIBERTY technology. Expand and protect the Company's global IP portfolio, which creates barriers to entry, and allows the Company to monetize its innovative technology. Leverage the strong balance sheet to fully execute its near and medium-term commercial strategy in the U.S. and globally, and to support its product development pipeline.